Reported 1 day ago
Akero Therapeutics, Inc. (NASDAQ:AKRO) is highlighted as one of the best-performing healthcare stocks, with a year-to-date performance of 43.24%. The company's lead product, Efruxifermin, is currently in Phase 3 trials for treating metabolic diseases, positioning it favorably in the market. Analysts maintain a positive outlook, with Buy ratings and attractive price targets set by major firms like Bank of America. Despite its potential, some analysts suggest that certain AI stocks may offer even greater investment returns.
Source: YAHOO